MedTrace Logo

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

NCT05447637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-07-07

No results posted yet for this study

Summary

This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with genetic testing, through a post-test survey to be completed 60-90days after results have been received and discussed with their provider.

Conditions

Interventions

DIAGNOSTIC_TEST

Invitae multi-cancer gene panel

Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.

Sponsors & Collaborators

  • Invitae Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-07-01
Completion
2022-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447637 on ClinicalTrials.gov